Nantcell Inc., the Patrick Soon-Shiong-backed company built in part with funds from the blockbuster albumin-bound chemotherapy Abraxane (nab-paclitaxel), has exclusively licensed Cytrx Corp.'s aldoxorubicin, another albumin-bound therapy, to incorporate into the treatment of multiple tumor types in combination with other immuno-oncology and cell-based therapies.